UCB Revenue and Competitors

Atlanta, GA USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • UCB's estimated annual revenue is currently $3.1B per year.(i)
  • UCB's estimated revenue per employee is $201,000

Employee Data

  • UCB has 15362 Employees.(i)
  • UCB grew their employee count by 4% last year.

UCB's People

NameTitleEmail/Phone
1
Regulatory Process & Data OwnerReveal Email/Phone
2
VPReveal Email/Phone
3
CFO | Commercial FinanceReveal Email/Phone
4
Executive Assistant to VP Head Group FinanceReveal Email/Phone
5
CEO & Chairman the Executive CommitteeReveal Email/Phone
6
Executive Assistant to VP Head Talent Acquisition, Learning & DevelopmentReveal Email/Phone
7
Assistant to VP & Head Talent Acquisition & DevelopmentReveal Email/Phone
8
Head Global Engineering & Facilities, VPReveal Email/Phone
9
Head Global Clinical Development, VPReveal Email/Phone
10
Personal Assistant to VP, Non-Clinical DevelopmentReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$24.5M1228%N/AN/A
#2
$10.7M53-17%N/AN/A
#3
$9.2M462%N/AN/A
#4
$24.1M1205%N/AN/A
#5
$7.2M36-20%N/AN/A
#6
$27.7M138-30%N/AN/A
#7
$39.8M19837%N/AN/A
#8
$0.5M525%$50MN/A
#9
$13.7M68-7%N/AN/A
#10
$10.3M5111%N/AN/A
Add Company

What Is UCB?

UCB aspires to be the patient-centric global biopharmaceutical leader, transforming the lives of people living with serious diseases. The company employs more than 8 000 people dedicated to the research, development and commercialisation of innovative medicines and patient solutions. Operating in more than 40 countries, UCB generated revenues of € 3.2 billion in 2011.

keywords:N/A

N/A

Total Funding

15362

Number of Employees

$3.1B

Revenue (est)

4%

Employee Growth %

N/A

Valuation

N/A

Accelerator

UCB News

2022-04-20 - UCB's General Meeting of Shareholders 2022

UCB's General Meeting of Shareholders 2022. For financial year 2021: Gross dividend of € 1.30 per share (+ 2.36%), payable 3 May 2022; All...

2022-04-20 - Two more ventures join UCB's Digital Care Transformation ...

Julia Amunts of PeakProfiling “Working alongside the team of UCB will support us in validating our voice technology that can potentially act...

2022-04-20 - UCB (OTCMKTS:UCBJF) Downgraded by Zacks Investment ...

According to Zacks, “UCB SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in providing therapy for...

2017-09-27 - Engage Therapeutics Announces $23 Million Series A Financing

SUMMIT, N.J.--(BUSINESS WIRE)--Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a new rescue therapy for people who experience uncontrolled epileptic seizures, announced today the closing of its $23 million Series A financing round. Engage will use the proceeds fr ...

2017-09-27 - Lumira Capital Joins $23M Series A for Engage Therapeutics

SUMMIT, N.J.--(BUSINESS WIRE)--Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a new rescue therapy for people who experience uncontrolled epileptic seizures, announced today the closing of its $23 million Series A financing round. Engage will use the proceeds fr ...